Single concentration loss of activity assay provides an improved assessment of drug-drug interaction risk compared to IC50-shift.

about

Single concentration loss of activity assay provides an improved assessment of drug-drug interaction risk compared to IC50-shift.

Item

http://www.wikidata.org/entity/Q53155407

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

Single concentration loss of a ...... n risk compared to IC50-shift.

@en

Single concentration loss of a ...... n risk compared to IC50-shift.

@nl

type

Item

label

Single concentration loss of a ...... n risk compared to IC50-shift.

@en

Single concentration loss of a ...... n risk compared to IC50-shift.

@nl

prefLabel

Single concentration loss of a ...... n risk compared to IC50-shift.

@en

Single concentration loss of a ...... n risk compared to IC50-shift.

@nl

P1476

Single concentration loss of a ...... n risk compared to IC50-shift.

@en

P2093

Bradley K Wong

http://www.w3.org/2001/XMLSchema#string

Mey Lee

http://www.w3.org/2001/XMLSchema#string

Simon G Wong

http://www.w3.org/2001/XMLSchema#string

P2860

Risk assessment for drug-drug interaction caused by metabolism-based inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery process

Drug-drug interactions via mechanism-based cytochrome P450 inactivation: points to consider for risk assessment from in vitro data and clinical pharmacologic evaluation.

Drug-drug interactions of new active substances: mibefradil example.

Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4.

Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring.

Grapefruit juice-drug interaction studies as a method to assess the extent of intestinal availability: utility and limitations.

Exploring concepts of in vitro time-dependent CYP inhibition assays.

Impact of mechanism-based enzyme inactivation on inhibitor potency: implications for rational drug discovery.

IC50-based approaches as an alternative method for assessment of time-dependent inhibition of CYP3A4.

An evaluation of the dilution method for identifying metabolism-dependent inhibitors of cytochrome P450 enzymes.

P304

953-966

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/00498254.2016.1143139

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-03-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26956546

http://www.w3.org/2001/XMLSchema#string